methotrexate + silymarin

Methotrexate + silymarin is a combination of two agents used together primarily to enhance therapeutic efficacy and reduce toxicity in certain clinical settings. Methotrexate is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, thereby blocking DNA synthesis and cell replication. It is widely used in the treatment of malignancies (such as acute lymphoblastic leukemia) and autoimmune diseases (such as rheumatoid arthritis). Silymarin, a flavonolignan complex extracted from the seeds of Silybum marianum (milk thistle), exhibits antioxidant, anti-inflammatory, cytoprotective, and hepatoprotective properties. The most active component of silymarin is silibinin. When combined with methotrexate: - Silymarin has been shown to protect against methotrexate-induced hepatic and renal toxicity by reducing oxidative stress markers (e.g., malondialdehyde), inflammatory cytokines (e.g., TNF-α), apoptotic markers (e.g., caspase-3), while increasing antioxidant capacity[2][5][7]. - In patients with rheumatoid arthritis or cancer receiving methotrexate therapy, co-administration with silymarin or its main component silibinin can improve clinical outcomes by further reducing disease activity scores and inflammatory cytokines such as IL-6, IL-8, TNF-α; it may also increase anti-inflammatory cytokines like IL-10[1][4]. This combination does not have a unique brand name but has been studied in both preclinical models and human trials for its synergistic effects on efficacy enhancement (including overcoming drug resistance) as well as organ protection.

Other names

methotrexate and silymarinMTX + silymarinmethotrexate and milk thistle